Abiopharma

🔍 O'Hare Robert (Executive)

Company: Affirm Holdings, Inc. (AFRM)

Report Date: 2026-09-01

Detailed Transactions and Holdings:

• Acquired 11,987 shares of Class A Common Stock (Direct)
  Date: 2026-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 30,466.00 | transaction_form_type: 4
• Sold 6,101 shares of Class A Common Stock at $69.94 per share (Direct)
  Date: 2026-09-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 24,365.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 15,545 shares of Class A Common Stock at $71.59 per share (Direct)
  Date: 2026-09-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 8,820.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 200 shares of Class A Common Stock at $72.51 per share (Direct)
  Date: 2026-09-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 8,620.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 5,886 shares of Class A Common Stock at $74.02 per share (Direct)
  Date: 2026-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,734.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 702 shares of Restricted Stock Units (Derivative)
  Date: 2026-09-01 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F6, F7, F7
• Sold 5,019 shares of Restricted Stock Units (Derivative)
  Date: 2026-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 20,075.00 | transaction_form_type: 4 | Footnotes: F6, F8, F8
• Sold 2,128 shares of Restricted Stock Units (Derivative)
  Date: 2026-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 17,022.00 | transaction_form_type: 4 | Footnotes: F6, F9, F9
• Sold 1,357 shares of Restricted Stock Units (Derivative)
  Date: 2026-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 10,853.00 | transaction_form_type: 4 | Footnotes: F6, F10, F10
• Sold 2,781 shares of Restricted Stock Units (Derivative)
  Date: 2026-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 22,244.00 | transaction_form_type: 4 | Footnotes: F6, F11, F11

Footnotes:

• F1: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the settlement of shares of Common Stock underlying the Reporting Person's restricted stock units that vested on September 1, 2026.
• F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026.
• F3: Represents the weighted average sale price of the shares sold from $71.25 to $72.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: Represents the weighted average sale price of the shares sold from $72.51 to $72.54 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: Represents the weighted average sale price of the shares sold from $73.84 to $74.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• F7: The RSUs vested in equal monthly installments from October 1, 2022 until August 1, 2023. Beginning September 1, 2023, the RSUs vest in equal quarterly installments, subject to the Reporting Person's continued employment with the Issuer as of each vesting date. This grant has no expiration date.
• F8: The RSUs vest as to 25% of the shares on September 1, 2024 and the remainder vest in 12 equal quarterly installments over the subsequent three years, subject to the Reporting Person's continuous service with the Issuer as of each vesting date. This grant has no expiration date.
• F9: The RSUs vest as to 25% of the shares on September 1, 2025 and the remainder vest in 12 equal quarterly installments over the subsequent three years, subject to the Reporting Person's continuous service with the Issuer as of each vesting date. This grant has no expiration date.
• F10: The RSUs vest in equal quarterly installments for a period of four years beginning December 1, 2024, the vesting commencement date, subject to the Reporting Person's continued employment with the Issuer as of each vesting date.
• F11: The RSUs vest in equal quarterly installments for a period of three years beginning December 1, 2025, the vesting commencement date, subject to the Reporting Person's continued employment with the Issuer as of each vesting date.